Alzheimer's Disease
Conditions
Keywords
Alzheimer's disease, cognitive function, brain glucose utilization, FDG-PET
Brief summary
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this population will also be studied. These results will be used to design larger studies of MSDC-0160 in persons with mild Alzheimer's disease.
Detailed description
The specific objective is to examine the feasibility of conducting future large scale studies on the efficacy of MSDC-0160 in persons with mild Alzheimer's disease. Efficacy and safety will be assessed as follows: 1. Estimate the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The a priori regions of interest (ROI) will include five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. 2. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose utilization, using FDG-PET voxel-based analysis. 3. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests. 4. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale. 5. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. 6. Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin, TNFα, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the apolipoprotein ε4 allele explain the heterogeneity in baseline level of brain glucose utilization and, in MSDC-0160 users, 3-month brain glucose utilization. 7. Explore whether changes in peripheral inflammatory biomarkers correlate with changes in 3-month brain glucose utilization in MSDC-0160 users. 8. Investigate the safety of MSDC-0160 versus placebo using reports of early study termination and adverse events.
Interventions
DRUGMSDC-0160
MSDC-0160 150 mg capsules given once daily for 90 days
DRUGPlacebo
Placebo capsules given once daily for 90 days
Sponsors
Metabolic Solutions Development Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Male or females 55-85 years of age. 2. Females should be either postmenopausal or surgically sterilized. Males with female partners of child-bearing potential must use contraception if engaging in sexual intercourse. 3. Diagnosis of probable Alzheimer's disease based on NIA-AA criteria with MMSE scores of 20 or greater. 4. Willing and able to take part in up to six study visits over a 5-month period, with the support of a caregiver as needed. 5. Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study, with the support of a caregiver as needed.
Exclusion criteria
1. Diagnosis of diabetes, including use of anti-diabetic medications, or fasting plasma glucose \>125 mg/dl or Hemoglobin A1c\>6.4%. 2. Unable to participate in FDG-PET scanning, including: * Inability to cooperate/claustrophobia (no sedation offered for this protocol). * Inability to lie still on the scanner bed for 40 minutes. * Total radiation dose exposure to the subject in any given year exceeds the limits of annual and total dose commitment of 50 mSv (5 REMs). The two FDG-PET scans will result in an approximate exposure of 10 mSv (1 REM). 3. Diagnosis of significant neurological/psychiatric disease other than AD, including, but not limited to, any of the following: vascular dementia according to NINDS-AIREN criteria, space occupying cerebral lesion, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, and seizures. 4. History of heart failure (including CHF). 5. Previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to screening. 6. Inability to undergo a clinical (1.5T) MRI of the brain without contrast and lack of a usable (less the 12 months prior to screening) MRI on record. Contraindications to undergoing an MRI of the brain include, but are not limited to, pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; and, other magnetic, electronic or mechanical implants or clinical findings that in the judgment of the investigator would pose a potential hazard in combination with MRI. 7. ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine \>1.5 mg/dL in men or \> 1.4 mg/dL in women. 8. Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the subject unlikely to complete the study. 9. Malignancy (other than non-melanoma skin cancer) within the last 5 years. 10. Known history of HIV, hepatitis B, or hepatitis C. 11. Blood pressure greater than 160/100 mmHg. Subjects with elevated BP will be allowed at the discretion of the principal investigator. Individuals with hypertension must have been stabilized to the current treatment regimen for at least 6 weeks prior to screening and not need adjustments to their treatment regimen during the entire study period. 12. Change in other medications to treat Alzheimer's disease within 3 months prior to screening. Change in medication to treat other conditions within 6 weeks prior to screening or during the study period. 13. Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds, or any of their stated ingredients. 14. History of alcohol or drug abuse within 6 months of screening. 15. Have participated in an investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration. 16. Single 12-lead ECG demonstrating a QTcB \>450 msec or other clinically significant finding at screening. A single repeat ECG may be done at the investigator's discretion. 17. Any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following: history of major gastrointestinal tract surgery, currently active inflammatory bowel syndrome. 18. Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Days 1(baseline) and 91 | Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is ≥0 indicates maintenance of brain glucose utilization, whereas values \<0 indicate a decline in brain glucose utilization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Global Cognitive Function Tests | Days 1 (baseline) and 91 | Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175. |
| Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale | Days 1 (baseline) and 91 | Alzheimer's Disease Assessment Scale - Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment). |
| Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale | Days 1 (baseline) and 91 | Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175. |
| Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks | Days 1(baseline) and 91 | Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| MSDC-0160 Capsules MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days | 16 |
| Placebo Capsules Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days | 13 |
| Total | 29 |
Baseline characteristics
| Characteristic | MSDC-0160 Capsules | Placebo Capsules | Total |
|---|---|---|---|
| Age, Continuous | 72.3 years STANDARD_DEVIATION 8.8 | 71.0 years STANDARD_DEVIATION 8 | 71.7 years STANDARD_DEVIATION 8.3 |
| Mini-Mental State Examination Score | 22.8 units on a scale STANDARD_DEVIATION 2.4 | 25.2 units on a scale STANDARD_DEVIATION 2.1 | 23.9 units on a scale STANDARD_DEVIATION 2.6 |
| Presence of an Apolipoprotein E e4 allele Apo E e4 allele present | 10 participants | 9 participants | 19 participants |
| Presence of an Apolipoprotein E e4 allele Apo E e4 allelle absent | 6 participants | 4 participants | 10 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 14 Participants | 11 Participants | 25 Participants |
| Sex: Female, Male Female | 8 Participants | 8 Participants | 16 Participants |
| Sex: Female, Male Male | 8 Participants | 5 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 7 / 16 | 5 / 13 |
| serious Total, serious adverse events | 1 / 16 | 0 / 13 |
Outcome results
Primary
Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum
Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is ≥0 indicates maintenance of brain glucose utilization, whereas values \<0 indicate a decline in brain glucose utilization.
Time frame: Days 1(baseline) and 91
Population: Intent-to-treat
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MSDC-0160 Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Parietal cingulate | 0.01 Ratio | Standard Deviation 0.02 |
| MSDC-0160 Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Medial temporal cortex | 0.01 Ratio | Standard Deviation 0.02 |
| MSDC-0160 Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Lateral temporal cortex | 0.00 Ratio | Standard Deviation 0.02 |
| MSDC-0160 Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Ant. cing.-frontal cortex | 0.00 Ratio | Standard Deviation 0.02 |
| MSDC-0160 Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Posterior cingulate | 0.01 Ratio | Standard Deviation 0.03 |
| Placebo Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Ant. cing.-frontal cortex | -0.03 Ratio | Standard Deviation 0.03 |
| Placebo Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Posterior cingulate | -0.02 Ratio | Standard Deviation 0.03 |
| Placebo Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Parietal cingulate | -0.03 Ratio | Standard Deviation 0.03 |
| Placebo Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Lateral temporal cortex | -0.02 Ratio | Standard Deviation 0.03 |
| Placebo Capsules | Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum | Medial temporal cortex | -0.01 Ratio | Standard Deviation 0.02 |
Secondary
Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale
Alzheimer's Disease Assessment Scale - Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment).
Time frame: Days 1 (baseline) and 91
Population: One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the ADAS-Cog tests at both study time points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MSDC-0160 Capsules | Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale | 0.69 Scores on a scale | Standard Deviation 3.62 |
| Placebo Capsules | Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale | 2.21 Scores on a scale | Standard Deviation 2.87 |
Secondary
Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale
Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.
Time frame: Days 1 (baseline) and 91
Population: One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the executive function tests at both study time points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MSDC-0160 Capsules | Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale | -0.04 z-score | Standard Deviation 0.25 |
| Placebo Capsules | Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale | 0.00 z-score | Standard Deviation 0.45 |
Secondary
Change From Baseline in Global Cognitive Function Tests
Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.
Time frame: Days 1 (baseline) and 91
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MSDC-0160 Capsules | Change From Baseline in Global Cognitive Function Tests | -0.06 z-scores | Standard Deviation 0.11 |
| Placebo Capsules | Change From Baseline in Global Cognitive Function Tests | 0.03 z-scores | Standard Deviation 0.59 |
Secondary
Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks
Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity.
Time frame: Days 1(baseline) and 91
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MSDC-0160 Capsules | Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks | 17822 micromol/L | Standard Deviation 10940 |
| Placebo Capsules | Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks | 795 micromol/L | Standard Deviation 4477 |